article

Drug Target Review – Issue 3 2018

Posted: 3 September 2018 | | No comments yet

In this issue: pharmacological targeting of mitochondrial dysfunction in Parkinson’s disease, the evolving role of three dimensional in-vitro cell culture techniques in drug discovery, and NGS: hunting mysterious ‘Dark Matter Genome’ towards rewriting the rules of genetic diseases.

Drug Target Review 3 2018 magazine

In this issue:

  • FOREWORD: The changing face in drug discovery
    Pushpanathan Muthuirulan, Harvard University
  • ASSAYS: Applications of high content screening in autophagy
    Saba Ezazi Erdi, Ole Pless and Sheraz Gul Fraunhofer-IME
  • UPSTREAM BIOPROCESSING: Upstream cell culture processes for the production of therapeutic proteins
    Jonathan P. Wels Principal Scientist, Centre for Process Innovation, National Biologics Manufacturing Centre, Darlington, UK
  • SYNTHETIC BIOLOGY: Synthetic biology in drug discovery
    Dr Tim Brears, Chief Executive Officer, Evonetix
  • ANTIBODIES: Aggregate formation for monoclonal antibodies
    Tony Edge, Agilent Technologies, UK
  • PARKINSON’S: Pharmacological targeting of mitochondrial dysfunction in Parkinson’s disease: approaches and perspectives
    Iryna Mankovska, Olga Gonchar, Kateryna Rozova, Larysa Bratus and Iryna Karaban
  • FLOW CYTOMETRY: How recent advances in flow cytometry can aid drug discovery
    Rachael Walker, Head of Flow Cytometry at Babraham Institute, Cambridge, UK and Derek Davies, Science Technology Platform Head, The Francis Crick Institute
  • METABOLICS: Metabolomics in drug and biomarker discovery
    Giuseppe Astarita, Senior Scientist, Denali Therapeutics
  • NEXT-GENERATION SEQUENCING: Hunting mysterious ‘Dark Matter Genome’ towards rewriting the rules of human genetic diseases
    Pushpanathan Muthuirulan, Harvard University, Cambridge

 

 

Issue 3 2018 of Drug Target Review is restricted - login or subscribe free to access

Drug Target Review 3 2018 coverThank you for visiting our website. To access this content in full you'll need to login. It's completely free to subscribe, and in less than a minute you can continue reading. If you've already subscribed, great - just login.

Why subscribe? Join our growing community of thousands of industry professionals and gain access to:

  • quarterly issues in print and/or digital format
  • case studies, whitepapers, webinars and industry-leading content
  • breaking news and features
  • our extensive online archive of thousands of articles and years of past issues
  • ...And it's all free!

Click here to Subscribe today Login here

 


Send this to a friend